23 May 2013 - 23 May 2013 - US in-vitro diagnostics company ERBA Diagnostics Inc (NYSEMKT:ERB) said yesterday it had been informed by the NYSE MKT exchange of not being compliant with the market's requirement for timely filing of a quarterly report on form 10-Q for the first trimester of 2013.

The letter, received on May 17, also states that not filing a quarterly report on form 10-Q on time is a material violation of the company's listing agreement with NYSE MKT and as such, the latter has the right to suspend and, unless quick corrective action is taken, remove ERBA Diagnostics' securities from the exchange.

The firm has been granted a period by the end of the month to submit a plan to regain compliance by August 15. ERBA Diagnostics is already working on such a plan, it added.

The company has delayed the submission of its quarterly report on form 10-Q due to delays in filing of its 2012 annual report on the same form.